Treatment with gefitinib at 0.3 μM resulted in a modest but statistically significant reduction in MMP-2 expression to approximately 0.9-fold (p < 0.001), suggesting a slight inhibitory effect on this matrix-degrading enzyme, which plays a critical role in tumor invasion and metastasis. Here, MMP2 is linked to neoplasm.